Bacterial-directed enzyme-prodrug therapy (BDEPT) uses tumour-tropic bacteria armed with a geneticallyencoded prodrug-converting enzyme to sensitise tumours to a systemically-administered prodrug. A strong bystander effect (i.e., efficient bacteria-to-tumour transfer of activated prodrug metabolites) is critical to maximise tumour cell killing and avoid bacterial self-sterilisation. To investigate the bystander effect in bacteria we developed a sensitive screen that utilised two Escherichia coli strains grown in co-culture. The first of these was an activator strain that overexpressed the E. coli nitroreductase NfsA, and the second was a nitroreductase null recipient strain bearing an SOS-GFP DNA damage responsive gene construct. In this system, induction of GFP by genotoxic prodrug metabolites can only occur following their transfer from the activator to the recipient cells. This can be monitored both in fluorescence based microtitre plate assays and by flowcytometry, enabling modelling of the abilities of diverse nitroaromatic prodrug metabolites to exit a Gram negative vector. Activator strain -expresses the prodrug activating enzyme but does not report on presence of the active prodrug metabolite. Recipient strain -does not express the prodrug activating enzyme but can report on receipt of the active prodrug metabolite. Negative control strain -does not express the prodrug activating enzyme and does not report on presence of the active prodrug metabolite (used in co-culture with the recipient strain to control for baseline levels of signal generated by the prodrug acting on the recipient strain). Positive control strain -expresses the prodrug converting enzyme and can report on receipt of the active prodrug metabolite (used to set fluorescence gates during flow cytometry and to optimise the prodrug concentration(s) used in the assay).
Specification
Activator strain -expresses the prodrug activating enzyme but does not report on presence of the active prodrug metabolite. Recipient strain -does not express the prodrug activating enzyme but can report on receipt of the active prodrug metabolite. Negative control strain -does not express the prodrug activating enzyme and does not report on presence of the active prodrug metabolite (used in co-culture with the recipient strain to control for baseline levels of signal generated by the prodrug acting on the recipient strain). Positive control strain -expresses the prodrug converting enzyme and can report on receipt of the active prodrug metabolite (used to set fluorescence gates during flow cytometry and to optimise the prodrug concentration(s) used in the assay).
Experimental design:
Protocol for evaluating the ability of activated prodrug metabolites to exit a bacterial activator cell and cause damage to surrounding cells, by co-culture of an activating strain with a recipient strain that lacks the activating enzyme, but carries a reporter construct able to quantify the damage. Trial registration: N/A Ethics:
N/A
Value of the Protocol
Direct relevance to BDEPT -First assay to measure the ability of prodrug metabolites to exit a model bacterial vector rather than tumour activator cells. Affordability and ease of use. Miniaturised -Assay optimised for 384-well microtitre plates, reducing synthesis costs for analysis of bespoke prodrug candidates.
Description of protocol
The bystander effect (i.e., the ability of activated prodrug metabolites to transfer from activating cells to neighbouring cells) is essential to bacterial-directed enzyme-prodrug therapy (BDEPT), as failure of the prodrug to exit the activating bacterium will negate the therapy. We present here the first protocol to quantify the ability of activated prodrugs to exit a bacterial activator cell, based on coculture of an activator strain expressing a prodrug converting enzyme with a recipient strain that can quantify drug-induced damage. Both flow cytometry and microplate methodologies are described.
Background
The ability of activated prodrug metabolites to transfer from activating cells to neighbouring cells (i.e., the bystander effect) is a critical aspect of enzyme-prodrug therapies [1] . For viral-directed enzyme-prodrug therapy (VDEPT), transfer of prodrug metabolites from activating cells to untransfected adjacent cells has been modelled using mixed multilayer human cell cultures [2] . The bystander effect is even more important in bacterial-directed enzyme-prodrug therapy (BDEPT) where failure of the prodrug to exit the activating bacterium will negate the therapy entirely. However, an effective model to assay the abilities of different prodrugs to exit an activating bacterial cell has not previously been described. To address this, we developed a model that employs bacterial activator cells (over-expressing a prodrug-converting nitroreductase) in co-culture with nitroreductase-null SOS-GFP recipient cells (able to report on the levels of DNA damage induced via the bystander effect of activated nitroaromatic genotoxins [3] . As the model required considerable optimisation, we describe here a detailed protocol to enable implementation of the model in any laboratory with fluorescent plate-reader or flow cytometry capabilities.
Materials
High-grade sterile LB Antibiotics (for maintenance of plasmids; for us these were ampicillin and spectinomycin) IPTG Sterile culture vials/tubes for cell growth Sterile 384-well microtitre plates Shaking incubator for culture growth Spectrophotometer for monitoring cell growth Microplate photometer for monitoring cell growth and fluorescence Flow cytometer for monitoring fluorescence of individual bacteria Software appropriate for analysis of flow cytometry data Bacterial strains, genes and plasmids Activator strain -expresses the prodrug activating enzyme but does not report on presence of the active prodrug metabolite. Recipient strain -does not express the prodrug activating enzyme but can report on receipt of the active prodrug metabolite. Negative control strain -does not express the prodrug activating enzyme and does not report on presence of the active prodrug metabolite (used in co-culture with the recipient strain to control for baseline levels of signal generated by the prodrug acting on the recipient strain). Positive control strain -expresses the prodrug converting enzyme and can report on receipt of the active prodrug metabolite (used to set fluorescence gates during flow cytometry and to optimise the prodrug concentration(s) used in the assay).
In our previous study [3] and henceforth throughout this protocol, the prodrug converting enzymes were bacterial nitroreductases. The nitroreductase genes were PCR-amplified from genomic DNA stocks and cloned into the ampicillin resistant expression plasmid pUCX as previously described [4, 5] . Our primary focus was the E. coli nitroreductase NfsA, which exhibits high level activity with a broad range of nitroaromatic substrates [6] .
Our activator strain and recipient strain were the E. coli strains 7NT and SOS-R4 as previously described [7] . These are isogenic derivatives of the E. coli strain W3110 with seven endogenous nitroreductase candidate genes (nfsA, nfsB, azoR, nemA, mdaB, yieF and ycaK) deleted to reduce background activation of nitroaromatic prodrugs together with deletion of the tolC transporter gene to restrict active efflux of unreduced prodrug. The 7NT activator strain was transformed with pUCX expressing a prodrug-converting nitroreductase, and additionally transformed with empty pCDFDuet plasmid to confer spectinomycin resistance. The recipient strain was SOS-R4 (7NT pre-transformed with pANODuet, a spectinomycin resistant plasmid expressing a gfp reporter gene under control of the SOS-responsive sfiA promoter), further transformed with empty pUCX to confer ampicillin resistance. The negative control strain was 7NT transformed with empty pUCX; and the positive control strain was SOS-R4 transformed with pUCX expressing the prodrug-converting nitroreductase.
Optimizing prodrug concentration
To accurately model the bystander effect in bacteria, the prodrug concentration must be optimised to ensure acceptable growth inhibition of the positive control strain. We have previously found that a greater than 20 % decrease in culture turbidity in response to prodrug challenge, relative to an unchallenged control, can cause a reduction in output during SOS assays [4] . To enable comparison of multiple prodrugs, use empirical testing to determine concentrations of each prodrug that elicit comparable levels of reporter gene expression from the positive control strain, without causing more than 20 % growth inhibition. In our assays, the prodrug challenge time was typically 3.5À4 h to generate a measurable difference in GFP fluorescence signal between the prodrug challenged and unchallenged conditions in a 384-well microtitre assay using the SOS-R4 strain. However for nonnitroaromatic prodrugs this incubation time may need to be optimised. For nitroreductase assays metronidazole has a negligible bacterial bystander effect [3] and can be used as a nil bystander control to compare to other prodrugs.
Method
Bacterial bystander assays performed in 384 well microtitre plates Evaluation of cell-to-cell transfer of activated prodrug metabolites in E. coli can be performed in 384 well microtitre plates (Fig. 1 ).
Test condition: co-culture of activator strain (nitroreductase-expressing 7NT) and recipient strain (nitroreductase null SOS-R4) challenged with the prodrug. Control condition: co-culture of negative control strain (nitroreductase null 7NT) and recipient strain (nitroreductase null SOS-R4) that are together challenged with the prodrug.
Procedure
1 Overnight cultures of a nitroreductase-expressing 7NT activator strain, a nitroreductase null 7NT control strain, and the SOS-R4 recipient strain were inoculated in 3 mL aliquots of LBASG media (lysogeny broth supplemented with 100 mg ml À1 ampicillin, 50 mg ml À1 spectinomycin and 0.2 % glucose (w/v)) were established in sterile 15 ml centrifuge tubes and incubated overnight for 16 h at 30 C with shaking at 200 rpm. 2 The following morning, cultures were visually assessed to ensure each had achieved expected levels of turbidity (spectrophotometric measurement not essential at this stage, but if performed the OD 600 should exceed 2.5). Next, 0.5 mL of each overnight culture were used to inoculate distinct day cultures of 10 mL of LBASGI (LBASG supplemented with 50 mM IPTG, to induce nitroreductase expression), which were then incubated at 30 C, 200 rpm for 3 h. Prior to prodrug challenge all cultures were diluted using fresh LBASGI media to an OD 600 of 0.8. ii Control condition: pipette 15 mL of the nitroreductase null 7NT negative control day culture into the assigned wells.
iii Pipette 15 mL of the nitroreductase null SOS-R4 recipient strain day culture into all of these wells to bring the final volume to 60 mL per well. ii Control condition: pipette 100 mL of the nitroreductase null 7NT negative control day culture into a 1.5 mL centrifuge tube.
iii Add 900 mL of nitroreductase null SOS-R4 recipient strain day culture to each tube and mix well by pipetting.
iv Dispense 30 mL into each of the assigned wells to bring the final volume to 60 mL per well.
c For each strain, grow replicate cultures in both control and challenge media to enable background levels of growth inhibition and GFP expression (recipient strain only) to be ascertained.
i For each of the three strains, pipette 30 mL of day culture into separate wells containing 30 mL control or 30 mL challenge media. d A protective barrier of 60 mL of sterile media was dispensed into the immediately surrounding wells to prevent uneven exposure to incubation conditions, which can influence the growth of cultures. e After dispensing all the day cultures into the microtitre plate, mix well by pipetting. f Record the OD 600 for all experimental wells on a microplate photometer. g Incubate the microtitre plate at 30 C, 200 rpm for 3.5 h, after which the OD 600 and GFP fluorescence (excitation 490 nm/emission 530 nm) should be recorded on a microplate photometer. 4 To calculate the fold increase in fluorescence resulting from cell-to-cell transfer of activated prodrug metabolites (Fig. 1B) . a Derive the mean fluorescence of the technical replicates for the Test condition and divide this by the mean fluorescence of the technical replicates for the corresponding Control condition. b Assess growth inhibition (OD 600 for prodrug challenged versus unchallenged conditions) to ensure that the level of inhibition does not exceed 20 %. 5 In this microtitre assay, biological replicates are derived from independent overnight cultures.
Technical replicates are replicate microtitre cultures derived from a single overnight culture for each condition.
Bacterial bystander assays performed using flow cytometry
Evaluation of cell-to-cell transfer of activated prodrug metabolites in a population of E. coli can be performed using flow cytometry immediately following the microtitre plate assay (Fig. 2) . Note that two additional sets of replicates must be established in the microtitre plate: one comprising 100 % positive control cells, challenged with prodrug as per the Test condition; and one comprising 100 % negative control cells without prodrug challenge. These replicates will enable the upper and lower limits of the selection gates to be set.
Conditions to set fluorescence selection gates:
Negative control strain (nitroreductase null 7NT) in LBASGI media without prodrug. Use to set lower limit of selection gate to remove background auto fluorescence. Positive control strain (nitroreductase-expressing SOS-R4) expresses the prodrug converting enzyme. Use to set upper limit of selection gate to capture the highest expected fluorescence in co-cultures.
was dispensed into the immediately surrounding wells. B. Measuring the bacterial bystander effect by calculating the fold increase in fluorescence resulting from cell-to-cell transfer of activated prodrug metabolites. To calculate the fold difference in fluorescence, average the raw fluorescence units of each technical replicate performed for the Test condition (purple bar) and then divide by the average fluorescence of the technical replicates performed for the corresponding Control condition (tan bar). Error bars represent the standard deviation of the average fold increase in GFP induction across a minimum of three biological replicates, each derived from an independent overnight culture. A fold increase in fluorescence >>1 indicates a high bacterial bystander effect was detected, as per Prodrug Z (CB1954) (red bar) while a fold increase in GFP close to 1 indicates a poor bacterial bystander effect as per metronidazole (blue bar). iii Select the prodrug conditions you are going to collect data for. Pipette 25 mL of the pooled culture sample for the positive control strain challenged with that prodrug into one of the polypropylene tubes containing PBS and mix by vortexing for five seconds. iv The positive control strain is used to set the upper limit of the selection gate to capture the highest expected fluorescence in co-cultures. v Adjust the GFP parameters of the flow cytometer until the cells with the highest GFP fluorescence in the population are captured and displayed in the dot plot and histogram. An upper limit is achieved when no significant number of cells is captured beyond this GFP parameter. vi For each new prodrug tested, reset the upper limit of the selection gate to the upper-most GFP signal recorded for the positive control strain challenged with that prodrug. d On a Becton Dickinson FACSCanto II (BD Biosciences San Jose, CA) our typical parameters were FSC 570, SSC 450 and GFP 555. All data was collected within 2.5 h of removal from the incubator for each biological replicate, using the lowest flow rate of approximately 12 mL of sample per minute (BD LSR II User's Guide). 4 Collecting data for the Test and Control conditions a For the pooled technical replicates of each prodrug challenge condition, pipette 25 mL of the pooled culture sample into one of the polypropylene tubes containing PBS and mix by vortexing for five seconds. For each sample collect 30,000 fluorescent events within the selection gate using a low flow rate while recording all data. It is advisable to also monitor the proportion of events recorded outside the selection gates; if this proportion is substantial then it may be necessary to re-set the selection gate boundaries. b Monitor the geometric mean of the GFP fluorescence for all events within the selection gate.
c Perform this sample collection on the flow cytometer on two more 25 mL aliquots of the pooled sample, to generate three technical flow cytometry replicates for each Test and Control condition.
i Monitor and record overlap in the selection gate for the technical replicates using overlay histograms (Fig. 2B ).
standard deviation of the average fold increase in GFP induction across a minimum of three biological replicates. A fold increase in GFP induction significantly greater than 1 for the Test relative to the Control indicates a high bacterial bystander effect, as with Prodrug Z (red bar), while a fold increase in GFP close to 1 indicates a poor bacterial bystander effect as with metronidazole (blue bar). (Fig. 2C) . i Average the geometric mean recorded from the three technical replicates of the Test condition then divide this by the average geometric mean recorded from the three technical replicates of the Control condition. Repeat for each prodrug tested. ii Values significantly >1 indicate activation of fluorescence in the recipient cell population as a consequence of the bystander effect. c We typically performed at least three biological replicates, derived from independent overnight cultures, for each prodrug condition under investigation.
Additional information
In previous work we have described our development of a GFP-SOS reporter strain to quantify activation of nitroaromatic prodrugs by an over-expressed bacterial nitroreductase [7] and our application of this system to enable directed evolution of superior nitroreductase variants [8] . Here we detail how this system can be adapted to detect activation of prodrugs by non-reporter strains in coculture, followed by transfer of activated prodrug metabolites to a recipient reporter strain. This bacterial bystander assay is robust, economical and easily implemented. As it can be performed in 384 well microtitre plates, prodrug consumption is low. Importantly, our model informs directly on the relative abilities of prodrug metabolites to exit Gram negative bacterial activator cells. Using this technique we have observed that prodrugs can differ in their suitability for VDEPT versus BDEPT applications [3] , which highlights the importance of evaluating enzyme-prodrug combinations in models relevant to the intended GDEPT vector. Taking into account the fundamental physiological differences associated with different gene-delivery systems will facilitate the identification of optimal enzyme-prodrug combinations for each setting as new vectors and prodrugs are developed.
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